Bispecific antibodies as emerging pharmaceuticals for tumor immunotherapy

Drugs of the Future

Volumn 30, Issue 10, 2005, Pages 1013-1016

  Aramwit, Pornanong ^a   Liu, Xiaoyu ^b   Cong, Xinyi ^c   Lam, Laura ^c   Cao, Ying ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Zhejiang Hisun Pharmaceutical Co Ltd   (China)

^c BioMedSci Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BISPECIFIC ANTIBODY; CASPASE; CD4 ANTIGEN; CD8 ANTIGEN; CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FAS LIGAND; FC RECEPTOR; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; GRANZYME B; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELPHALAN; PACLITAXEL; RITUXIMAB; SOMATOMEDIN RECEPTOR; THIOTEPA; TOSITUMOMAB I 131; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONJUGATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HYBRIDOMA; METASTASIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW;

EID: 30744445691     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.10.943922     Document Type: Review

References (13)

1. Cao, Y., Lam, L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 2003, 55: 171-97.
2. Russell, J.H., Ley, T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20: 323.
3. Armstrong, A., Eck, S.L. EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003, 2: 320-6.
4. Wimberger, P., Xiang, W., Mayr, D. et al. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM/CD3-bispecific antibody. Int J Cancer 2003, 105:241-8.
5. Brischwein, K., Schlereth, B., Guller, B. et al. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2005, Advance publication.
6. Willems, A., Schoonooghe, S., Eeckhout, D., Jaeger, G.D., Grooten, J., Mertens, N. CD3 × CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation. Cancer Immunol Immunother 2005, Advance publication.
7. Cerwenka, A., Lanier, L.L. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001, 1: 41.
8. van Ojik, H.H., Valerius, T. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Crit Rev Oncol Hematol 2001, 38: 47-61.
9. Shahied, L.S., Tang, Y., Alpaugh, R.K., Somer, R., Greenspon, D., Weiner, L.M. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004, 279: 53907-14.
10. Bruenke, J., Barbin, K., Kunert, S. et al. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcγRIII (CD16). Br J Haematol 2005, 130: 218-28.
11. Heiss, M.M., Strohlein, M.A., Jager, M. et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005, 117: 435-43.
12. Stemmler, H.J., Salat, C., Lindhofer, H. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: A pilot study. Anticancer Res 2005, 25: 3047-54.
13. Lu, D., Zhang, H., Koo, H. et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005, 280: 19665-72